EGFR and non-small cell lung carcinoma: Encouraging clinical activity profile of osimertinib combinations in EGFR-mutation-positive NSCLC patients; emergence of interstitial lung disease in combination patients warrants further investigation (durvalumab arm now discontinued) [Ongoing Phase Ib study]